Monday, March 27, 2023
Clinical Advances in
Recent advancements have been made in the treatment of human epidermal growth factor receptor 2 (HER2)-positive cancers (breast cancer and gastrointestinal [GI] cancers). This has led to the development of new HER2 testing guidelines in breast cancer and new strategies are emerging for managing patients with low HER2 expression and those who are refractory to HER2-targeted therapies. HER3 overexpression has also been observed in various cancers and is currently being investigated as a therapeutic target. This curriculum discusses the new HER2 testing guidelines and explores the recent clinical advances and future prospects for HER2- and HER3-targeted therapy.
Supported by an independent educational grant from
Daiichi Sankyo
See All
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.
Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update.
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.
Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.
See All
Steering Committee Chair
Professor
Breast Center
University of Munich
Munich, Germany
Professor/Chairman
Inserm Unit U981
Institut Gustave Roussy
Villejuif, France
Head
Breast Cancer Program
IOB Institute of Oncology
Madrid & Barcelona
Ruber International Hospital
Madrid, Spain
Professor, Head Division of Early Drug Development,
Istituto Europeo di Oncologia,
University of Milan
Milan, Italy
Associate Attending, Breast Medicine
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York
Chief
Department of Gastrointestinal Oncology
National Cancer Center Hospital East
Kashiwa, Japan
Steering Committee Chair
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Daiichi Sankyo, Inc.; Novartis Pharmaceuticals Corporation; Roche
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Daiichi Sankyo, Inc.; Novartis Pharmaceuticals Corporation; Roche
Has disclosed the following relevant financial relationships
Received grants for clinical research from: AstraZeneca; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Pfizer, Inc.; Roche
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Athenex; Biothera Pharmaceuticals, Inc.; Celgene Corporation; Cellestia Biotech AG; Daiichi Sankyo, Inc.; Erytech Pharma; GlaxoSmithKline; Lilly USA, LLC; Merck Sharp & Dohme Corp.; Merus; Polyphor; Roche; Seattle Genetics, Inc.; SERVIER
Served as a speaker or a member of a speakers bureau for: Celgene Corporation; Eisai Inc.; Lilly USA, LLC; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche; Samsung
Received grants for clinical research from: ARIAD Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; Baxalta GmbH; Bayer HealthCare; Eisai Inc.; F. Hoffmann-La Roche Ltd; Guardant Health; Merck Sharp & Dohme Corp.; Pfizer Inc.; PIQUR Therapeutics AG; Puma Biotechnology; Roche; SERVIER
Owns stock, stock options, or bonds from: MedSIR
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Celltrion; Daiichi Sankyo, Inc.; Eli Lilly and Company; Foundation Medicine; Mylan Laboratories Inc.; Nanostring; Pfizer, Inc.; Roche; Samsung; Seattle Genetics, Inc.
Served as a speaker or a member of a speakers bureau for: Bristol-Myers Squibb Company; Celltrion; Daiichi Sankyo, Inc.; Eli Lilly and Company; Foundation Medicine; MSD; Mylan Laboratories Inc.; Nanostring; Novartis Pharmaceuticals Corporation; Pfizer, Inc.; Roche; Samsung; Seattle Genetics, Inc.
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Daiichi Sankyo, Inc.; Eli Lilly and Company; Genentech, Inc.; GlaxoSmithKline; Macogenics
Served as a speaker or a member of a speakers bureau for: Genentech, Inc.
Received grants for clinical research from: Daiichi Sankyo, Inc.; Eli Lilly and Company; Genentech, Inc.; GlaxoSmithKline; Macogenics; Novartis Pharmaceuticals Corporation; Seattle Genetics, Inc.; Synta
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Astellas Pharma, Inc.; Bristol-Myers Squibb Company; Eli Lilly and Company; MSD; Ono Pharmaceutical; Pfizer Inc.; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: Astellas Pharma, Inc.; Chugai Pharma; Daiichi Sankyo, Inc.; Dainippon Sumitomo Pharma; Eli Lilly and Company; MediScience; MSD; Ono Pharmaceutical; Taiho Pharmaceutical Co., Ltd.
Other: Honoraria: AbbVie Inc.; Novartis Pharmaceuticals Corporation; Yakult